Sun Pharmaceutical Industries
|
|
- Maria Shauna Parsons
- 5 years ago
- Views:
Transcription
1 Sun acquires Ranbaxy Gain size at a cost of margin premium April 09, 2014 Surajit Pal surajitpal@plindia.com Rating Accumulate Price Rs630 Target Price Rs646 Implied Upside 2.5% Sensex 22,702 Nifty 6,796 (Prices as on April 09, 2014) Trading data Market Cap. (Rs bn) 1,304.8 Shares o/s (m) 2, M Avg. Daily value (Rs m) Major shareholders Promoters 63.65% Foreign 22.49% Domestic Inst. 5.74% Public & Other 8.12% Stock Performance (%) 1M 6M 12M Absolute 2.9 (2.4) 45.2 Relative (0.7) (16.0) 22.1 How we differ from Consensus EPS (Rs) PL Cons. % Diff Price Performance (RIC: SUN.BO, BB: SUNP IN) (Rs) Apr 13 Jun 13 Source: Bloomberg Aug 13 Oct 13 Dec 13 Feb 14 Apr 14 Sun acquires Ranbaxy: Sun Pharma acquired Ranbaxy at an all stock deal of US$4bn, including equity value of US$3.2bn and debt of US$800m. Per deal, Ranbaxy to merge with Sun Pharma at a stock swap ratio of 0.8:1. This implies 16% dilution in Sun Pharma with addition of 478m shares at Rs.457/share to Ranbaxy. Additionally, Sun would also assume contingent liability of US$850mn in forex derivatives which were bought by Ranbaxy at US$/Rs42 44 in The duration of the derivative contracts is set to expire in 2016 with expiry of contract US$35mn/month. Merged entity to be domestic behemoth with 9.2% market share: Sun Pharma, post merger, will have market share of 9.2%, with few overlaps in CVs and Diabetetology. The merged entity has reached in a dominant position with its presence in top 4 cos in each of the to 10 therapeutic areas. The Top 10 therapeutic areas contribute 90% of Indian Pharma market. Sun s US Derma business to be major gainer: With acquisition of Ranbaxy, Sun Pharma to be number one in generic derma while it ranks number three in branded Derma business in US. Absorica s sales of US$100mn and sales team of 50 reps in US to be source of major synergy due to branded Derma business in DUSA and Taro Pharma. Drugs in anti acne, Actinic Keratosis and anti fungal to be Sun Pharma s key specialty business in US Derma post acquisition. Valuation Maintain Accumulate with TP Rs.646: While Sun Pharma management believes to achieve US$250m synergy in three years, we believe that Ranbaxy s single digit EBITDA margin, forex derivatives, high consultancy costs and high tax rate to be strong hangover in near term. FDA s approval in Nexium and Diovan could provide benefits of US$ m net income in short term. We maintain Accumulate and target price at Rs.646. Key financials (Y/e March) E 2015E 2016E Revenues (Rs m) 112, , , ,703 Growth (%) EBITDA (Rs m) 48,962 71,690 78,579 87,088 PAT (Rs m) 35,732 53,423 53,987 59,197 EPS (Rs) Growth (%) (21.3) (25.2) Net DPS (Rs) Profitability & Valuation E 2015E 2016E EBITDA margin (%) RoE (%) RoCE (%) EV / sales (x) EV / EBITDA (x) PE (x) P / BV (x) Net dividend yield (%) Source: Company Data; PL Research Event Update Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. Please refer to important disclosures and disclaimers at the end of the report
2 Sun Pharma s acquisition of Ranbaxy in all stock swap deal would create fourth largest generic company in the world with US$4.2bn sales and US$1.2bn EBITDA. Per agreement, Ranbaxy to merge with Sun Pharma and its shareholders would receive 0.8 shares of Sun Pharma against 1 share of Ranbaxy. Sun Pharma s acquisition would provide edge to its size of sales in US, India and ROW markets. With this acquisition, Sun Pharma to be ranked top in generic dermatology and ranked number three in branded dermatology business in US. The company also would be ranked top in domestic market with 9.2% market share. With acquisition of Ranbaxy, Sun Pharma s US sales to be US$2.2bn, India sales to be US$1.1bn and ROW sales to be US$0.9bn. The joint entity will have 445 ANDAs in markets with 184 ANDAs in pipeline in US. Sun would gain major access in ROW markets with few overlaps in Romania, South Africa, Russia, Malaysia and Brazil. The joint entity would however inherit USFDA s ban on four major plants Dewas, Poanta Sahib, Mohali and Toansa. All the four manufacturing facilities are included in Consent Decree (CD) signed between Ranbaxy and US FDA to achieve remediation for the plants. Sun Pharma s debt would be increased to US$800m and contingent liability with exposure of US$850m to forex derivatives. Overall, we analyse Sun Pharma s benefits vis à vis cost (qualitative and quantitative) of the acquisition in short term and long term: Revenue Contributions Exhibit 1: Ranbaxy Exhibit 2: Sun Pharma Exhibit 3: Merged Entity ROW 50 US 29 India 23 ROW 17 US 60 ROW 31 US 47 India 21 India 22 Source: Company Data, PL Research Source: Company Data, PL Research Source: Company Data, PL Research April 09,
3 Short Term benefits Approvals for Ranbaxy in Nexium (May 2014) and Diovan could lead to a net income of US$ m in most optimistic scenario, assuming API supply to be sourced from Sun Pharma. In case API is sourced from third party, we expect net income to be shared by 50% in Nexium and Diovan. We expect INR35.6 EPS from one off opportunity in Nexium and Diovan, assuming sharing of net income with third party API supplier Reduction of headcounts in sales reps could reduce cost of sales of Ranbaxy for domestic market Domestic market share of 9.2% could increase better pricing power and impart synergy through complimentary expansion of networks Addition of Ranbaxy s derma products including Absorica, Ximino and 13 brands bought from BMS. Sun Pharma also gain marketing team of 50 reps in US to synergy for Derma business in Taro and DUSA s franchise Short term negatives Increase uncertainty in financial performance with MTM value of forex derivatives (US$850m) and debt (US$800m) Increase leverage with US$800mn would reduce availability of cash (US$1.3bn) for international acquisition Reduce revenues in APIs as Ranbaxy voluntarily stopped production and global export of APIs from Toansa plant post US FDA s import alert on the plant. Also, there would be increase in production costs of Ohm Labs (Ranbaxy s US subsidiary) as supply of APIs from Toansa for internal consumptions to be stopped post US FDA ban Additional consultancy costs for remediation in Toansa and Mohali to be increased from Q1FY15. We believe that Ranbaxy currently incurs 3 4% of EBITDA margin on account of consultancy costs to achieve US FDA compliance for its four plants Cost of severance package for the joint entity post merger of Ranbaxy in Sun Pharma Operating margin (EBITDA) of the merged entity to be decreased to 28% 30% vs. Sun Pharma s EBITDA margin of 44%. Tax rate of merged entity to be increased as Ranbaxy s normalised tax rate is 20% while Sun Pharma s normalised tax rate is 15% 17% April 09,
4 Long term benefits Restructuring of Ranbaxy s operation along with efficient supply chain management to gain US$250m synergy in three years Key drugs from Ohm Labs could be produced in Sun Pharma s India plant to increase profitability. Site transfer of low margin products from ohm Labs could address capacity constraints in the plant Higher possibility of re approval of Mohali, Toansa and non sterile division of Dewas by US FDA. Approval of 15 ANDAs (as we believe) applied from Ohm Labs since We expect few more shared exclusivity could be possibility in long term Reduction in consultancy costs and streamlined operation could lead to increase operating margin Long term negatives In our view, Ranbaxy is unprepared in its product pipeline for addressing issues pertaining to patent cliff period post Three year patent exclusivity of Absorica to be expired in 2015 and likely to be genericised with launch of Mylan s generic. Currently, Absorica s sales are US$100m per annum While operating margin of Ranbaxy could be increased to 16 18%, the operating margin could not be matched with Sun Pharma s 44% EBITDA margin given the nature of products in Ranbaxy We believe that strong compliance lacunae in Poanta Sahib led to Ranbaxy s investment in Mohali for US market. This implies that Sun Pharma s expectation of US FDA approval for Poanta Sahib plant may come a cropper Dewas Plant is one of the oldest plant of Ranbaxy and profitable products such as Penems and Cipro were filed from sterile division of the plant. We believe that early relieve from Consent Decree could be possible only for non sterile division of Dewas plant while approval of Sterile division could take longer time to receive approval Average track record of resolution in CD takes 5 7 years for generic cos while patent holder cos takes 7 9 years. With the history of resolution achieved in CD, we expect Sun Pharma may regain compliance in Dewas in while Mohali and Toansa may receive earlier approval in 2016 Post approval of Mohali plant from US FDA in 2016, ANDA applications from Mohali plant would not be commercially viable Ranbaxy s single digit operating margin and net loss could reduce EPS of Sun Pharma in FY15E FY16E while increase sales by US$1.7bn. This implies lower ROI which may lead to reduction in premium valuation to peers April 09,
5 Income Statement (Rs m) Net Revenue 112, , , ,703 Raw Material Expenses 20,733 30,953 31,962 35,422 Gross Profit 92, , , ,281 Employee Cost 15,345 19,246 25,251 27,986 Other Expenses 27,958 38,491 40,791 45,207 EBITDA 48,962 71,690 78,579 87,088 Depr. & Amortization 3,362 4,104 4,688 5,396 Net Interest Other Income 3,881 5,239 5,396 5,558 Profit before Tax 49,050 72,361 78,810 86,693 Total Tax 8,456 10,854 15,762 17,339 Profit after Tax 40,595 61,507 63,048 69,354 Ex Od items / Min. Int. (6,939) (42,264) 9,061 10,157 Adj. PAT 35,732 53,423 53,987 59,197 Avg. Shares O/S (m) 1, , , ,071.2 EPS (Rs.) Cash Flow Abstract (Rs m) C/F from Operations 33,629 55,891 50,681 63,738 C/F from Investing (26,351) (2,468) (11,106) (11,328) C/F from Financing (6,713) (7,263) (6,994) (13,211) Inc. / Dec. in Cash ,160 32,581 39,199 Opening Cash 17,527 20,691 66,851 99,431 Closing Cash 20,691 66,851 99, ,630 FCFF 11,667 31,152 34,822 40,953 FCFE 11,057 31,280 35,281 41,490 Key Financial Metrics Growth Revenue (%) EBITDA (%) (3.8) PAT (%) (21.3) EPS (%) (21.3) (25.2) Profitability EBITDA Margin (%) PAT Margin (%) RoCE (%) RoE (%) Balance Sheet Net Debt : Equity (0.3) (0.3) (0.4) (0.5) Net Wrkng Cap. (days) Valuation PER (x) P / B (x) EV / EBITDA (x) EV / Sales (x) Earnings Quality Eff. Tax Rate Other Inc / PBT Eff. Depr. Rate (%) FCFE / PAT Source: Company Data, PL Research. Balance Sheet Abstract (Rs m) Shareholder's Funds 149, , , ,426 Total Debt 2,597 2,724 3,183 3,720 Other Liabilities 17,188 22,286 28,267 35,105 Total Liabilities 169, , , ,251 Net Fixed Assets 50,771 54,667 59,979 64,583 Goodwill 11,330 12,330 12,330 12,330 Investments 24,116 18,584 19,690 21,018 Net Current Assets 75, , , ,921 Cash & Equivalents 40,587 66,851 99, ,630 Other Current Assets 64,376 87, , ,848 Current Liabilities 29,953 34,537 37,014 37,558 Other Assets 8,456 10,140 11,656 13,400 Total Assets 169, , , ,251 Quarterly Financials (Rs m) Y/e March Q1FY14 Q2FY14 Q3FY14 Q4FY14E Net Revenue 34,822 41,921 42,866 41,499 EBITDA 15,306 18,284 19,751 20,074 % of revenue Depr. & Amortization 978 1,005 1,050 1,072 Net Interest Other Income 954 1,196 1,602 1,487 Profit before Tax 15,063 18,358 20,236 20,429 Total Tax 1,511 2,760 2,438 3,473 Profit after Tax (12,761) 13,623 15,311 14,668 Adj. PAT 12,413 13,623 15,311 14,668 Key Operating Metrics Formulations 106, , , ,040 India Formulations 29,657 36,775 43,394 50,771 US Formulations 61,538 97, , ,477 ROW Formulations 15,344 20,480 24,121 28,791 APIs 7,549 7,614 8,651 9,553 Source: Company Data, PL Research. April 09,
6 Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai , India Tel: (91 22) Fax: (91 22) Rating Distribution of Research Coverage % of Total Coverage 60% 50% 40% 30% 20% 10% 0% 52.7% 25.9% 20.5% 0.9% BUY Accumulate Reduce Sell PL s Recommendation Nomenclature BUY : Over 15% Outperformance to Sensex over 12 months Accumulate : Outperformance to Sensex over 12 months Reduce : Underperformance to Sensex over 12 months Sell : Over 15% underperformance to Sensex over 12 months Trading Buy : Over 10% absolute upside in 1 month Trading Sell : Over 10% absolute decline in 1 month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly This document has been prepared by the Research Division of Prabhudas Lilladher Pvt. Ltd. Mumbai, India (PL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. April 09,
Source: Company Data; PL Research
US generics, low RM costs lead to margin surprise May 08, 2014 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs990 Target Price Rs1,156 Implied Upside 16.8% Sensex 22,324 Nifty
More informationTata Steel. Source: Company Data; PL Research
Earnings marred by forex losses and initial start up costs November 12, 2012 Kamlesh Bagmar kamleshbagmar@plindia.com +91-22-66322237 Mandar Dhavle mandardhavle@plindia.com +91-22-66322258 Rating Accumulate
More informationCig volumes surprise. Source: Company Data; PL Research
Cig volumes surprise July 26, 2012 Gautam Duggad gautamduggad@plindia.com +91-22-66322233 Rating BUY Price Rs249 Target Price Rs275 Implied Upside 10.4% Sensex 16,640 Nifty 5,043 (Prices as on July 26,
More informationHindustan Zinc. Strong show, H2 to be stronger than H1. Source: Company Data; PL Research
Strong show, H2 to be stronger than H1 October 21, 2014 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price Rs164 Target Price Rs200
More informationGMR Infrastructure. Airport revenues on a thaw, Power awaiting its turn. Q3FY13 Result Update
Airport revenues on a thaw, Power awaiting its turn February 11, 2013 Rupa Shah rupashah@plindia.com +91-22-66322244 Rating Accumulate Price Rs19 Target Price Rs21 Implied Upside 10.5% Sensex 19,461 Nifty
More informationBharat Forge. Strong traction in exports. (our estimate Rs730m). Source: Company Data; PL Research
Strong traction in exports January 24, 2011 Surjit Arora surjitarora@plindia.com +91 22 66322235 Rating Accumulate Price Rs348 Target Price Rs415 Implied Upside 19.3% Sensex 19,008 (Prices as on January
More informationNeed to pull up the socks. Source: Company Data; PL Research
Need to pull up the socks May 11, 2012 Rupa Shah rupashah@plindia.com +91-22-66322244 Rating Accumulate Price Rs148 Target Price Rs162 Implied Upside 9.5% Sensex 16,293 Nifty 4,929 (Prices as on May 11,
More informationBritannia Industries
Volumes impacted by slowdown; Margin expands May 27, 2014 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs870 Target
More informationGujarat State Fertilisers & Chemicals
Capro benzene spreads remain weak; near term muted October 25, 2013 Balwindar Singh balwindarsingh@plindia.com +91-22-66322239 Rating Accumulate Price Rs54 Target Price Rs60 Implied Upside 11.1% Sensex
More informationTVS Motors. Source: Company Data; PL Research
Margins trajectory looking up ; Accumulate November 01, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs709
More informationCummins India. Source: Company Data; PL Research
Technology leadership, cost optimization key focus October 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs852
More informationPantaloon Retail India
Sequential moderation in SSS growth May 16, 211 Gautam Duggad gautamduggad@plindia.com +91 22 66322233 Rating BUY Price Rs241 Target Price Rs332 Implied Upside 37.8% Sensex 18,531 (Prices as on May 13,
More informationMaruti Suzuki. Source: Company Data; PL Research
Healthy operating performance; Accumulate October 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs5,860 Target Price Rs6,356 Implied Upside 8.5% Sensex 27,916 Nifty
More informationApollo Tyres. Profitability likely to improve. Source: Company Data; PL Research
Profitability likely to improve November 09, 2011 Surjit Arora surjitarora@plindia.com +91-22-66322235 Rating Accumulate Price Rs59 Target Price Rs66 Implied Upside 11.9% Sensex 17,362 (Prices as on November
More informationIndraprastha Gas. Growth traction continues. Source: Company Data; PL Research
Growth traction continues June 28, 216 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating BUY Price Rs65 Target Price Rs632 Implied Upside 4.5% Sensex 26,43 Nifty 8,95 (Prices as on June 27,
More informationBharat Petroleum Corporation
Higher inventory loss drag earnings August 14, 2017 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating BUY Price Rs479 Target Price Rs553 Implied Upside 15.4% Sensex 31,449 Nifty 9,794 (Prices
More informationGlenmark Pharmaceuticals
Mupirocin: Glenmark to monopoly post FDA s WL to GSK July 22, 2016 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating BUY Price Rs865 Target Price Rs1,186 Implied Upside 37.1% Sensex 27,803 Nifty
More informationMahindra & Mahindra. Source: Company Data; PL Research
Tractors drive Q2 performance; Accumulate November 11, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs1,242 Target Price Rs1,503 Implied Upside 21.0% Sensex 26,819 Nifty
More informationSource: Company Data; PL Research
Strong inflow growth, renewable/railways key drivers October 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,063
More informationCoal India. Source: Company Data; PL Research
Misses estimates; Higher costs dims hope for earnings recovery February 13, 2017 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Rating Reduce Price Rs325 Target Price Rs320 Implied Upside 1.5%
More informationPersistent Systems. Growth led by Enterprise Retain BUY. Source: Company Data; PL Research
Growth led by Enterprise Retain BUY October 26, 20 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs669 Target Price Rs780
More informationNIIT Technologies. Strong growth in core services. Source: Company Data; PL Research
Strong growth in core services October 19, 2015 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs494 Target Price Rs625
More informationMphasis. Increased confidence on margins. Source: Company Data; PL Research
Increased confidence on margins July 25, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating BUY Price Rs540 Target Price Rs570 Implied Upside 5.6% Sensex 28,095 Nifty 8,636 (Prices as
More informationMaruti Suzuki. In a league of its own ; Buy. Source: Company Data; PL Research
In a league of its own ; Buy October 28, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs8,115 Target Price Rs9,250
More informationAurobindo Pharma. Source: Company Data; PL Research
Sales miss on few approvals, earnings beats on better revenue May 31, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs786 Target Price Rs943 Implied Upside 2% Sensex 26,668 Nifty
More informationBharat Forge. Exports remain subdued, outlook better. Source: Company Data; PL Research
Exports remain subdued, outlook better November 08, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs850 Target Price Rs957 Implied Upside 12.6% Sensex 27,591 Nifty 8,544 (Prices
More informationAsian Paints. Source: Company Data; PL Research
Premium valuations to sustain, Accumulate October 4, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,1 Target Price Rs1,9 Implied
More informationCummins India. Growth/margin bottoming. Source: Company Data; PL Research
Growth/margin bottoming May 25, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs704 Target Price Rs928 Implied Upside 31.8%
More informationGlenmark Pharmaceuticals
Costcontrol does the wonder, beat est; Consistency required November 03, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs627 Target Price Rs733 Implied Upside 16.9% Sensex
More informationMaruti Suzuki. Source: Company Data; PL Research
Run continues, Royalty reduction positive ; Buy January 29, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs9,277
More informationAurobindo Pharma. Source: Company Data; PL Research
1QFY17 performance in line; H2FY17 guided to be better August 24, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs788 Target Price Rs943 Implied Upside 19.7% Sensex 28,060 Nifty
More informationCrompton Greaves. Looking to exit overseas Power segment! Source: Company Data; PL Research
Looking to exit overseas Power segment! May 29, 2015 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs166 Target Price Rs204
More informationAurobindo Pharma. Source: Company Data; PL Research
Babystep in US OTC Diversifying patent cliff uncertainty November 13, 2014 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating BUY Price Rs1,062 Target Price Rs1,308 Implied Upside 23.2% Sensex 28,009
More informationDr. Reddy's Laboratories
New US generics, India sales to counter price erosion in FY17 May 12, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs2,971 Target Price Rs2,993 Implied Upside.7% Sensex
More informationDr. Reddy's Laboratories
PSAI, India saves the day; US generics to face more October 25, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs3,200 Target Price Rs2,945 Implied Upside 8.0% Sensex 28,091
More informationCadila Healthcare. Source: Company Data; PL Research
Q4 broadly in line; US remain cornerstone of growth May 26, 2018 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs383 Target Price Rs438 Implied Upside 14.4% Sensex 34,925 Nifty
More informationThermax. Source: Company Data; PL Research
Near term outlook muted, working on building a strong base November 11, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price
More informationCoal India. Source: Company Data; PL Research
Lower costs and higher scale off sets weaker realisations February 12, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price Rs305
More informationJK Lakshmi Cement. Source: Company Data; PL Research
Expansions on schedule; lower costs to aid margins June 28, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price Rs385 Target
More informationAsian Paints. Source: Company Data; PL Research
Premium Valuations to sustain, Accumulate May, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,18 Target Price Rs1,171 Implied
More informationIs bet on big data going to be even bigger? Source: Company Data; PL Research
Is bet on big data going to be even bigger? April 23, 2014 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs531 Target Price
More informationSiemens. Railways and T&D driving inflows. Source: Company Data; PL Research
Railways and T&D driving inflows November 23, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,055 Target Price Rs1,230
More informationSpiceJet. Healthy operating performance in Q2. Source: Company Data; PL Research
Healthy operating performance in Q2 November 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs65 Target Price Rs115 Implied Upside 76.9% Sensex 26,316 Nifty 8,114 (Prices
More informationBharat Electronics. Best defence play. Source: Company Data; PL Research
Best defence play October 31, 2017 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs185 Target Price Rs219 Implied Upside 18.4%
More informationBritannia Industries
Sustains momentum; Input cost gains peaked out November 09, 2015 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price
More informationLupin Result beats expectations; Near term revenue drivers improves grows visibility
Result beats expectations; Near term revenue drivers improves grows visibility February 10, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs1,495 Target Price Rs1,730 Implied
More informationAurobindo Pharma. Source: Company Data; PL Research
US injectable, OTC, EU geared for higher growth in FY19E February 09, 2018 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs602 Target Price Rs909 Implied Upside 51.0% Sensex 34,413
More informationCadila Healthcare. Source: Company Data; PL Research
Sales marginally better, EBITDA disappoints February 08, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs326 Target Price Rs338 Implied Upside 3.7% Sensex 24,617 Nifty 7,489
More informationMphasis. Source: Company Data; PL Research
Setting path for growth in Direct Channel, Retain Accumulate June 18, 2015 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating Accumulate
More informationCadila Healthcare. Source: Company Data; PL Research
remain tepid; Valuation reflects near term potential May 29, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs444 Target Price Rs460 Implied Upside 3.6% Sensex 31,028 Nifty
More informationCoal India. Source: Company Data; PL Research
Realisations drive the beat; E auction to surprise positively in H2 November 13, 2015 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY
More informationSource: Company Data; PL Research
Soft performance; Organization restructuring on the cards January 21, 2011 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Rating Accumulate Price Rs456 Target Price Rs550 Implied Upside 20.6% Sensex
More informationSource: Company Data; PL Research
Result disappoints; Competition catching up in key drugs May 14, 2015 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs1,632 Target Price Rs1,823 Implied Upside 11.7% Sensex
More informationHindalco Industries. Source: Company Data; PL Research
Beats its own best; building up for next leg of growth May 08, 2018 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Amit Khimesra amitkhimesra@plindia.com +91 22 66322244 Rating BUY Price Rs239
More informationHindustan Zinc. Source: Company Data; PL Research
Beat on all counts; tight supplies to keep the Zinc prices firm October 20, 2015 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price
More informationDr. Lal PathLabs. Source: Company Data; PL Research
Operating efficiency, Seasonal tailwind lead growth, margin November 09, 2017 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs832 Target Price Rs963 Implied Upside 15.7% Sensex
More informationCoal India. Source: Company Data; PL Research
Earnings marred by weak realisations; Downgrade to Accumulate September 14, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating Accumulate
More informationAllcargo Logistics. Source: Company Data; PL Research
Slow capex continue to impact PES, weak show continues May 24, 2018 Keyur Pandya keyurpandya@plindia.com +912266322247 R Sreesankar rsreesankar@plindia.com +912266322214 Rating Accumulate Price Rs120 Target
More informationEicher Motors. Continues to ride high! Accumulate. Source: Company Data; PL Research
Continues to ride high! Accumulate November 14, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs30,083 Target
More informationCummins India. Focusing on growth in core segments. Source: Company Data; PL Research
Focusing on growth in core segments June 07, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs681 Target Price Rs857 Implied
More informationCadila Healthcare. Source: Company Data; PL Research
Result is in line; Tall guidance for US, Delivery remains clouded May 15, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs327 Target Price Rs338 Implied Upside 3.4% Sensex 25,490
More informationLarsen & Toubro. Decent performance! Source: Company Data; PL Research
Decent performance! July 30, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating BUY Price Rs1,558 Target Price Rs1,590 Implied Upside 2.1%
More informationTech Mahindra. Source: Company Data; PL Research
Margin beat driven by Headcount reduction November 01, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs489 Target Price Rs535 Implied Upside 9.4% Sensex 33,600 Nifty 10,441 (Prices
More informationGlenmark Pharmaceuticals
Sales beat, Oneoff play spoilsport with headline margins May 15, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs869 Target Price Rs1,186 Implied Upside 36.5% Sensex 25,490 Nifty
More informationCadila Healthcare. Source: Company Data; PL Research
Overall performance disappoints, headwinds continue October 26, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs388 Target Price Rs337 Implied Upside 13.1% Sensex 27,837 Nifty
More informationUltratech Cement. Source: Company Data; PL Research
Higher realisations drove the show; Price led recovery still away April 25, 2018 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Amit Khimesra amitkhimesra@plindia.com +91 22 66322244 Rating Accumulate
More informationTata Motors. Source: Company Data; PL Research
JLR margin disappoints, Standalone turning around; Accumulate February 06, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate
More informationCrompton Greaves Consumer Electricals
Enough headroom for growth in core categories February 20, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs232 Target Price
More informationLarsen & Toubro. Revenues a positive surprise...so is other income! Q1FY13 Result Update
Revenues a positive surprise...so is other income! July 23, 2012 Rupa Shah rupashah@plindia.com +91-22-66322244 Rating Accumulate Price Rs1,378 Target Price Rs1,517 Implied Upside 10.1% Sensex 16,877 Nifty
More informationReliance Industries. Impressive performance. Source: Company Data; PL Research
Impressive performance April 25, 2017 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating Accumulate Price Rs1,416 Target Price Rs1,343 Implied Upside 5.2% Sensex 29,656 Nifty 9,218 (Prices as
More informationIndraprastha Gas. Source: Company Data; PL Research
MNGL on an accelerated growth trajectory August 29, 2016 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating Accumulate Price Rs784 Target Price Rs725 Implied Upside 7.5% Sensex 27,782 Nifty
More informationSonata Software. Strong growth, reasonable valuations. Source: Company Data; PL Research
Strong growth, reasonable valuations August 16, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs160 Target Price Rs200 Implied Upside 25.0% Sensex 31,771 Nifty 9,897 (Prices as
More informationSource: Company Data; PL Research
Sales beat, headline margins miss on pricing pressure in US August 10, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs1,608 Target Price Rs1,419 Implied Upside 11.8% Sensex
More informationCadila Healthcare. Source: Company Data; PL Research
US, India traction lead Q2 beat; Sustainability to drive valuation November 14, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs449 Target Price Rs519 Implied Upside 15.6%
More informationCrompton Greaves Consumer Electricals
Building strong base for growth May 16, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs228 Target Price Rs299 Implied
More informationNavneet Education. ILL loss hurts consolidated earnings growth. Source: Company Data; PL Research
ILL loss hurts consolidated earnings growth May 14, 2018 Keyur Pandya keyurpandya@plindia.com +91 22 66322247 R Sreesankar rsreesankar@plindia.com +91 22 66322214 Rating Accumulate Price Rs140 Target Price
More informationAshok Leyland. Source: Company Data; PL Research
Short term headwinds, structural story intact; Accumulate November 09, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate
More informationJindal Steel & Power
Good show in tough environment; well placed for long term BUY May 05, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating Accumulate Price
More informationHindustan Unilever. In the Pink of Health ; Accumulate. Source: Company Data; PL Research
In the Pink of Health ; Accumulate May 14, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating Accumulate Price Rs1,505 Target
More informationTata Motors. Source: Company Data; PL Research
Good show...but tread carefully ; Accumulate November 09, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs440
More informationJindal Steel & Power
Angul plant s Turnaround, a reality now; Reiterate BUY January 22, 2018 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Amit Khimesra amitkhimesra@plindia.com +91 22 66322244 Rating BUY Price
More informationHindustan Zinc. Source: Company Data; PL Research
Earnings in line; best placed in the base metal pack July 21, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating Accumulate Price Rs193
More informationNIIT Technologies. Source: Company Data; PL Research
Humble valuations leads to favourable risk return January 17, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs416 Target Price Rs520 Implied Upside 25.0% Sensex 27,236 Nifty 8,398
More informationSource: Company Data; PL Research
Portfolio realignment to yield benefits in medium term October 22, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating Accumulate Price Rs499 Target Price Rs600 Implied Upside 20.2% Sensex
More informationColgate Palmolive. Source: Company Data; PL Research
6 8% EPS cut as competitive threat looms large May 24, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price Rs835
More informationS Chand and Company. TP of Rs679 (implying PER of 20x FY19E earnings) Source: Company Data; PL Research
2Q is a non event, annual guidance remains intact November 20, 2017 Keyur Pandya keyurpandya@plindia.com +912266322247 R Sreesankar rsreesankar@plindia.com +912266322214 Rating BUY Price Rs461 Target Price
More informationEicher Motors. Source: Company Data; PL Research
Good show continues; In line quarter! Accumulate May 09, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs30,305
More informationTata Motors. Turnaround 2.0, Fit for future; BUY. Source: Company Data; PL Research
Turnaround 2.0, Fit for future; BUY June 06, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs296 Target Price Rs378
More informationSource: Company Data; PL Research
Valuations attractive, GST key to re rating : BUY January 20, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating BUY Price Rs274
More informationBharat Forge. Growth on all fronts; Accumulate. Source: Company Data; PL Research
Growth on all fronts; Accumulate November 08, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs728 Target Price
More informationMindtree. Source: Company Data; PL Research.
Strong Quarter, Guidance remains conservative April 18, 2018 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating Accumulate Price Rs866 Target Price Rs930 Implied Upside 7.4% Sensex 34,332 Nifty 10,526
More informationLarsen & Toubro. Source: Company Data; PL Research
Domestic execution showing positive trends July 28, 2017 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Rating BUY Price Rs1,159 Target Price Rs1,328 Implied Upside 14.6% Sensex 32,310 Nifty 10,015
More informationVa Tech Wabag. On track for a strong H2FY16. Source: Company Data; PL Research
On track for a strong H2FY16 November 09, 2015 Nishna Biyani nishnabiyani@plindia.com +91 22 66322239 Keyur Pandya keyurpandya@plindia.com +91 22 +91 22 66322247 Rating BUY Price Rs668 Target Price Rs1,000
More informationVRL Logistics. Steady show in tough environment. Source: Company Data; PL Research
Steady show in tough environment November 05, 2017 Keyur Pandya keyurpandya@plindia.com +91 22 66322247 R Sreesankar rsreesankar@plindia.com +91 22 66322214 Rating Accumulate Price Rs376 Target Price Rs370
More informationNIIT Technologies. Source: Company Data; PL Research
Third Consecutive quarter of strong execution January 20, 2018 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs728 Target Price Rs875 Implied Upside 20.2% Sensex 35,512 Nifty 10,895
More informationDabur India. Worst is over; Accumulate. Source: Company Data; PL Research
Worst is over; Accumulate October 31, 2017 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price Rs333 Target Price Rs342
More informationDabur India. Share gains power growth, Accumulate. Source: Company Data; PL Research
Share gains power growth, Accumulate May 02, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating Accumulate Price Rs371 Target
More informationBharat Electronics. Best defence bet! Source: Company Data; PL Research
Best defence bet! October 8, 212 Kunal Sheth kunalsheth@plindia.com +91-22-66322257 Riddhi Kothari riddhikothari@plindia.com +91-22-66322238 Rating BUY Price Rs1,224 Target Price Rs1,457 Implied Upside
More informationDabur India. Source: Company Data; PL Research
Deflation and poor demand impacts sales; Accumulate July 27, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price
More informationNIIT Technologies. Source: Company Data; PL Research
Improvement in revenue trajectory is key positive October 22, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating Accumulate Price Rs614 Target Price Rs670 Implied Upside 9.1% Sensex 32,584 Nifty
More information